NCT06881992View on ClinicalTrials.gov

A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism

PHASE3RecruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 16, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Tumor Hyperinsulinism (Tumor HI)
Interventions
DRUG

Ersodetug

Ersodetug (9 mg/kg) + SOC

Trial Locations (4)

44718

RECRUITING

Investigative Site, Canton

55905

RECRUITING

Investigative Site, Rochester

97239

RECRUITING

Investigative Site, Portland

02114

RECRUITING

Investigative Site, Boston

Sponsors

Lead Sponsor

Rezolute
All Listed Sponsors
lead

Rezolute

OTHER